• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    11/12/24 4:30:48 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDRX alert in real time by email
    SC 13G/A 1 sc13ga110022bdrx_11122024.htm

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 1)1

     

    Biodexa Pharmaceuticals PLC

     (Name of Issuer)

    Ordinary Shares, Nominal Value $.001 per share

     (Title of Class of Securities)

    59564R708

     (CUSIP Number)

    September 30, 2024

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 59564R708

     

      1   NAME OF REPORTING PERSON  
             
            Bigger Capital Fund, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         34,117,200 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              34,117,200 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            34,117,200 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 59564R708

      1   NAME OF REPORTING PERSON  
             
            Bigger Capital Fund GP, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         34,117,200 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              34,117,200 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            34,117,200 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 59564R708

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Capital Fund LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    4

    CUSIP No. 59564R708

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Capital LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    5

    CUSIP No. 59564R708

     

      1   NAME OF REPORTING PERSON  
             
            District 2 GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    6

    CUSIP No. 59564R708

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Holdings LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    35,143,600 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    7

    CUSIP No. 59564R708

     

      1   NAME OF REPORTING PERSON  
             
            Michael Bigger  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    69,260,800 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    69,260,800 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,612,800 Ordinary Shares (represented by 4,032 ADSs)
    69,260,800 Ordinary Shares issuable upon exercise of Warrants
    (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.2%*  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    8

    CUSIP No. 59564R708

    Item 1(a).Name of Issuer:

    Biodexa Pharmaceuticals PLC

    Item 1(b).Address of Issuer’s Principal Executive Offices:

    1 Caspian Point
    Caspian Way
    Cardiff, CF10 4DQ, United Kingdom

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

    Bigger Capital Fund, LP (“Bigger Capital”)

    2250 Red Springs Drive
    Las Vegas, NV 89135

    Citizenship: Delaware

     

    Bigger Capital Fund GP, LLC (“Bigger GP”)

    2250 Red Springs Drive
    Las Vegas, NV 89135

    Citizenship: Delaware

     

    District 2 Capital Fund LP (“District 2 CF”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 Capital LP (“District 2”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 GP LLC (“District 2 GP”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 Holdings LLC (“District 2 Holdings”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    Michael Bigger

    2250 Red Springs Drive
    Las Vegas, NV 89135

    Citizenship: USA

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    9

    CUSIP No. 59564R708

    Item 2(d).Title of Class of Securities:

    Ordinary Shares, nominal value .001 per share.

    Item 2(e).CUSIP Number:

    There is no CUSIP number assigned to the Ordinary Shares. The CUSIP number 59564R708 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on The Nasdaq Capital Market under the symbol “BDRX.” Each ADS represents 400 Ordinary Shares.

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
           
          If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership
    (a)Amount beneficially owned:

    As of November 11, 2024, Bigger Capital beneficially owned an aggregate of 34,117,200 Ordinary Shares issuable upon exercise of Warrants.

    10

    CUSIP No. 59564R708

    Bigger GP, as the general partner of Bigger Capital, may be deemed to beneficially own the 34,117,200 shares issuable upon exercise of Warrants beneficially owned by Bigger Capital.

    As of November 11, 2024, District 2 CF beneficially owned 1,612,800 Ordinary Shares (represented by 4,032 ADSs) and 35,143,600 Ordinary Shares issuable upon the exercise of Warrants.

    District 2, as the investment manager of District 2 CF, may be deemed to beneficially own the 1,612,800 Ordinary Shares beneficially owned by District 2 CF and the 35,143,600 Ordinary Shares issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    District 2 GP, as the general partner of District 2 CF, may be deemed to beneficially own the 1,612,800 Ordinary Shares beneficially owned by District 2 CF and the 35,143,600 Ordinary Shares issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    District 2 Holdings, as the managing member of District 2 GP, may be deemed to beneficially own the 1,612,800 Ordinary Shares beneficially owned by District 2 CF and the 35,143,600 Ordinary shares issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    Mr. Bigger, as the managing member of Bigger GP and the managing member of District 2 Holdings, may be deemed to beneficially own the (i) 1,612,800 Ordinary Shares beneficially owned by District 2 CF, (ii) 34,117,200 Ordinary Shares issuable upon exercise of Warrants owned by Bigger Capital, and (iii) 35,143,600 Ordinary Shares issuable upon exercise of Warrants owned by District 2CF.

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Ordinary Shares owned by another Reporting Person. Each of Bigger GP and Mr. Bigger disclaims beneficial ownership of Ordinary Shares beneficially owned by Bigger Capital. Each of District 2, District 2 GP, District 2 Holdings and Mr. Bigger disclaims beneficial ownership of the Ordinary Shares beneficially owned by District 2 CF. The filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

    (b)Percent of class:

    The percentages used in this Schedule 13G are calculated based on 5,808,395,322 Ordinary Shares outstanding, as reported by the Issuer in its Prospectus filed under Rule 424B3 on August 20, 2024, and assumes the exercise of the warrants held by Bigger Capital and District 2 CF.

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    See Cover Pages Items 5-9.

    (ii)Shared power to vote or to direct the vote

    See Cover Pages Items 5-9.

    11

    CUSIP No. 59564R708

    (iii)Sole power to dispose or to direct the disposition of

    See Cover Pages Items 5-9.

    (iv)Shared power to dispose or to direct the disposition of

    See Cover Pages Items 5-9.

    Item 5.Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8.Identification and Classification of Members of the Group.

    See Exhibit 99.1. Previously Filed.

    Item 9.Notice of Dissolution of Group.

    Not Applicable.

    Item 10.Certifications.

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    12

    CUSIP No. 59564R708

    SIGNATURE

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: November 12, 2024

    BIGGER CAPITAL FUND, LP   BIGGER CAPITAL FUND GP, LLC
         
    By: Bigger Capital Fund GP, LLC, its general partner   By:

    /s/ Michael Bigger

            Michael Bigger
    By:

    /s/ Michael Bigger

        Managing Member
      Michael Bigger      
      Managing Member      
          DISTRICT 2 CAPITAL LP
             
    DISTRICT 2 CAPITAL FUND LP   By:

    /s/ Michael Bigger

            Michael Bigger
    By: District 2 GP LLC, its general partner     Managing Member
             
    By:

    /s/ Michael Bigger

         
      Michael Bigger   DISTRICT 2 HOLDINGS LLC
      Managing Member      
          By:

    /s/ Michael Bigger

            Michael Bigger
    DISTRICT 2 GP LLC     Managing Member
             
    By:

    /s/ Michael Bigger

         
      Michael Bigger  

    /s/ Michael Bigger

      Managing Member   MICHAEL BIGGER

     

    13

    Get the next $BDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDRX

    DatePrice TargetRatingAnalyst
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $BDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

      March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the appointment of Precision for Medicine, LLC ("Precision") as the clinical research organization ("CRO") to conduct the European component of the upcoming registrational Phase 3

      3/6/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • Biodexa Appoints Ann Merchant to the Board of Directors

      Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023. Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and Externa

      12/29/23 4:05:00 AM ET
      $ALVO
      $BDRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BDRX
    SEC Filings

    See more
    • SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/4/25 8:30:26 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/2/25 5:24:24 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/2/25 5:23:46 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Biodexa Pharmaceuticals PLC with a new price target

      Ladenburg Thalmann initiated coverage of Biodexa Pharmaceuticals PLC with a rating of Buy and set a new price target of $8.00

      2/8/24 7:21:49 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

      June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes ("T1D"). The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and

      6/4/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shareholder Update

      May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced a brief update for shareholders. Financial positionAs of May 29, 2025, the Company had access to the following cash resources:   $ millionsCash at bank 5.7Cash in escrow for eRapa Phase 3 program 4.4  10.1   Undrawn CPRIT grant for eRapa Phase 3 program 11.9   Debt 0.5 The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially funded. Based on its latest projections,

      5/30/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Notice of General Meeting

      May 22, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Notice of General Meeting Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today. The Board of Directors is proposing four resolutions: Ordinary Resolutions       1.   That, subject to and conditional on the passing of Resolution 4, each of the issued ordinary shares of £0.001 each in the capital of the Comp

      5/22/25 4:30:00 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/20/24 11:56:39 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/14/24 5:12:47 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/12/24 4:30:48 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Financials

    Live finance-specific insights

    See more
    • Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

      CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications. When Biodexa sees potential, it acquires these products from third parties under licensing agreements which generally call

      11/21/24 7:35:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care